Illustration: Aïda Amer/Axios
Avalyn Pharma, a rare respiratory disease biotech, raised $300 million in an upsized IPO at $18 per share — the high end of its targeted range.
By the numbers: The upsized offering values Avalyn at about $753 million, based on outstanding shares.
